401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Manish Sharma; Ecaterina Ileana Dumbrava; Richard Carvajal; Daniel Catenacci; Leisha Emens; Glenn Hanna; Dejan Juric; Yoon-Koo Kang; Jeeyun Lee; Keun-Wook Lee; Bob Li; Kathleen Moore; Mark Pegram; Paula Pohlmann; Drew Rasco; Alexander Spira; Antoinette Tan; Ding Wang; Shelley Ackerman; Heidi LeBlanc; David Dornan; Marcin Kowanetz; Michael Alonso; Edith Perez; Edith Perez

doi:10.1136/jitc-2020-SITC2020.0401

Citation Tools

Regular and young investigator award abstracts

Clinical trials in progress

401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Sharma M, Dumbrava EI, Carvajal R, et al

401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0401

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password